Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel/cisplatin/5-fluorouracil chemoradiotherapy with or without cetuximab for resectable oesophageal adenocarcinoma
ACTRN12608000382370Phase 2Terminated
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Sep 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, docetaxel, cisplatin and fluorouracil in esophageal adenocarcinoma (EAC) and gastroesophageal adenocarcinoma (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Pathological complete response rate. Started Sep 2008; status: terminated.
02
Drugs
cetuximabdocetaxelcisplatinfluorouracil
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ACTRN12608000382370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000382370.